Aerovate Therapeutics Inc (NASDAQ: AVTE)’s stock price has plunge by -3.03relation to previous closing price of 2.64. Nevertheless, the company has seen a -4.66% plunge in its stock price over the last five trading sessions. businesswire.com reported 2024-12-28 that NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.
Is It Worth Investing in Aerovate Therapeutics Inc (NASDAQ: AVTE) Right Now?
Additionally, the 36-month beta value for AVTE is 1.00. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for AVTE is 19.59M and currently, short sellers hold a 9.48% ratio of that float. The average trading volume of AVTE on January 10, 2025 was 777.41K shares.
AVTE’s Market Performance
AVTE’s stock has seen a -4.66% decrease for the week, with a -4.83% drop in the past month and a 25.49% gain in the past quarter. The volatility ratio for the week is 2.37%, and the volatility levels for the past 30 days are at 3.35% for Aerovate Therapeutics Inc The simple moving average for the past 20 days is -1.76% for AVTE’s stock, with a -67.37% simple moving average for the past 200 days.
Analysts’ Opinion of AVTE
Many brokerage firms have already submitted their reports for AVTE stocks, with Wells Fargo repeating the rating for AVTE by listing it as a “Equal Weight.” The predicted price for AVTE in the upcoming period, according to Wells Fargo is $2 based on the research report published on June 18, 2024 of the previous year 2024.
Evercore ISI gave a rating of “In-line” to AVTE, setting the target price at $2 in the report published on June 18th of the previous year.
AVTE Trading at -1.99% from the 50-Day Moving Average
After a stumble in the market that brought AVTE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.10% of loss for the given period.
Volatility was left at 3.35%, however, over the last 30 days, the volatility rate increased by 2.37%, as shares sank -2.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.43% upper at present.
During the last 5 trading sessions, AVTE fell by -4.66%, which changed the moving average for the period of 200-days by -90.50% in comparison to the 20-day moving average, which settled at $2.61. In addition, Aerovate Therapeutics Inc saw -3.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVTE starting from RA CAPITAL MANAGEMENT, L.P., who purchase 928,110 shares at the price of $1.67 back on Jun 17 ’24. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 7,893,678 shares of Aerovate Therapeutics Inc, valued at $1,549,944 using the latest closing price.
Eldridge George A sale 15,000 shares at $25.03 during a trade that took place back on Jun 14 ’24, which means that Eldridge George A is holding 5,022 shares at $375,450 based on the most recent closing price.
Stock Fundamentals for AVTE
Current profitability levels for the company are sitting at:
- -663.67 for the present operating margin
- 0.38 for the gross margin
The net margin for Aerovate Therapeutics Inc stands at -622.14. The total capital return value is set at -1.12. Equity return is now at value -82.06, with -72.99 for asset returns.
Currently, EBITDA for the company is -81.31 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 316.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.78.
Conclusion
In conclusion, Aerovate Therapeutics Inc (AVTE) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
